Phase I trial of autologous CD19-targeted CAR-modified t cells as consolidation after purine analog-based first-line therapy in patients with previously untreated CLL.
Jae Hong Park
No relevant relationships to disclose
Isabelle Riviere
Consultant or Advisory Role - JUNO THERAPEUTICS
Stock Ownership - JUNO THERAPEUTICS
Xiuyan Wang
No relevant relationships to disclose
Shirley Bartido
No relevant relationships to disclose
Michel Sadelain
Consultant or Advisory Role - JUNO THERAPEUTICS
Stock Ownership - JUNO THERAPEUTICS
Renier J. Brentjens
Consultant or Advisory Role - JUNO THERAPEUTICS
Stock Ownership - JUNO THERAPEUTICS